Resource and infrastructure challenges on the RESIST-2 Trial: an implementation study of drug resistance genotype-based algorithmic ART switches in HIV-2-infected adults in Senegal

Trials

Dominique Faye¹  El Hadji Ibrahima Sall¹  Jean Philippe Diatta¹  Jean Jacques Malomar¹  Ousseynou Cisse¹  Jacques Sambou¹  Stephen E. Hawes²  Dana N. Raugi³  Robert A. Smith³  Geoffrey S. Gottlieb⁴  Khadim Faye⁵  Mouhamadou Baïla Diallo⁵  Moussa Seydi⁵  Binetou Diaw⁵  Khardiata Diallo⁵  Fatima Sall⁵ 

[1] Centre de Sante de Ziguinchor, Ziguinchor, Senegal;Department of Epidemiology, University of Washington, Seattle, WA, USA;Department of Global Health, University of Washington, Seattle, WA, USA;Department of Medicine, Division of Allergy & Infectious Diseases, Center for Emerging & Re-Emerging Infectious Diseases, University of Washington, Seattle, WA, USA;Department of Medicine, Division of Allergy & Infectious Diseases, Center for Emerging & Re-Emerging Infectious Diseases, University of Washington, Seattle, WA, USA;Department of Global Health, University of Washington, Seattle, WA, USA;Service des Maladies Infectieuses et Tropicales, Ibrahima Diop Mar, Centre Hospitalier National Universitaire de Fann, Universite Cheikh Anta Diop de Dakar, Dakar, Senegal;

关键词: HIV-2;    Antiretroviral therapy;    Viral suppression;    HIV treatment;    Point-of-care;    COVID-19;   

DOI  :  10.1186/s13063-021-05902-5

来源: Springer

【 摘 要 】

BackgroundSecond-line treatment of HIV-2 in resource-limited settings (RLS) is complicated by a lack of controlled trial data, limited availability of HIV-2-active antiretroviral drugs, and inadequate access to drug resistance testing. We conducted an implementation trial of a dried blood spot- (DBS) based, drug resistance genotype-informed antiretroviral therapy (ART) switching algorithm for HIV-2-infected patients in Senegal.MethodsHIV-2-infected adults initiating or receiving ART through the Senegalese national AIDS program were invited to participate in this single-arm trial. DBS from participants with virologic failure (defined as viral load (VL) > 250 copies/mL after > 6 months on the current ART regimen) were shipped to Seattle for genotypic drug resistance testing. Participants with evidence of drug resistance in protease or reverse transcriptase were switched to new regimens according to a pre-specified algorithm. Participant clinical and immuno-virologic outcomes were assessed, as were implementation challenges.ResultsWe enrolled 152 participants. Ten were initiating ART. The remainder were ART-experienced, with 91.0% virologically suppressed (< 50 copies/mL). Problems with viral load testing capability resulted in obtaining VL results for only 227 of 613 (37.0%) participant-visits. Six of 115 participants (5.2%) with VL available after > 6 months on current ART regimen experienced virologic failure, with per-protocol genotypic testing attempted. One additional test was performed for a participant with a VL of 222 copies/mL. Genotypes from three participants showed no evidence of major drug resistance mutations, two showed nucleoside reverse transcriptase inhibitor (NRTI) resistance, one showed both NRTI and protease inhibitor resistance, and one test failed. No integrase inhibitor resistance was observed. Five of six successfully-tested participants switched to the correct regimen or received additional adherence counseling according to the algorithm; the sixth was lost to follow-up. Follow-up VL testing was available for two participants; both of these were virally suppressed (< 10 copies/mL). The trial was terminated early due to the COVID-19 pandemic (which prevented further VL and genotypic testing), planned rollout of dolutegravir-based 1st-line ART, and funding.ConclusionsThe RESIST-2 trial demonstrated that a DBS-based genotypic test can be used to help inform second-line ART decisions as part of a programmatic algorithm in RLS, albeit with significant implementation challenges.Trial registrationClinicalTrials.govNCT03394196. Registered on January 9, 2018.

【 授权许可】

CC BY